Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

26 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Genetic modulation of the Let-7 microRNA binding to KRAS 3'-untranslated region and survival of metastatic colorectal cancer patients treated with salvage cetuximab-irinotecan.
Graziano F, Canestrari E, Loupakis F, Ruzzo A, Galluccio N, Santini D, Rocchi M, Vincenzi B, Salvatore L, Cremolini C, Spoto C, Catalano V, D'Emidio S, Giordani P, Tonini G, Falcone A, Magnani M. Graziano F, et al. Among authors: spoto c. Pharmacogenomics J. 2010 Oct;10(5):458-64. doi: 10.1038/tpj.2010.9. Epub 2010 Feb 23. Pharmacogenomics J. 2010. PMID: 20177422 Clinical Trial.
Intratumoural FOXP3-positive regulatory T cells are associated with adverse prognosis in radically resected gastric cancer.
Perrone G, Ruffini PA, Catalano V, Spino C, Santini D, Muretto P, Spoto C, Zingaretti C, Sisti V, Alessandroni P, Giordani P, Cicetti A, D'Emidio S, Morini S, Ruzzo A, Magnani M, Tonini G, Rabitti C, Graziano F. Perrone G, et al. Among authors: spoto c. Eur J Cancer. 2008 Sep;44(13):1875-82. doi: 10.1016/j.ejca.2008.05.017. Epub 2008 Jul 9. Eur J Cancer. 2008. PMID: 18617393
Bevacizumab in association with de Gramont 5-fluorouracil/folinic acid in patients with oxaliplatin-, irinotecan-, and cetuximab-refractory colorectal cancer: a single-center phase 2 trial.
Vincenzi B, Santini D, Russo A, Spoto C, Venditti O, Gasparro S, Rizzo S, Zobel BB, Caricato M, Valeri S, Coppola R, Tonini G. Vincenzi B, et al. Among authors: spoto c. Cancer. 2009 Oct 15;115(20):4849-56. doi: 10.1002/cncr.24540. Cancer. 2009. PMID: 19626652 Free article. Clinical Trial.
High concordance of BRAF status between primary colorectal tumours and related metastatic sites: implications for clinical practice.
Santini D, Spoto C, Loupakis F, Vincenzi B, Silvestris N, Cremolini C, Canestrari E, Graziano F, Galluccio N, Salvatore L, Caraglia M, Zito FA, Colucci G, Falcone A, Tonini G, Ruzzo A. Santini D, et al. Among authors: spoto c. Ann Oncol. 2010 Jul;21(7):1565. doi: 10.1093/annonc/mdq318. Ann Oncol. 2010. PMID: 20573852 Free article. No abstract available.
Cetuximab in small bowel adenocarcinoma: a new friend?
Santini D, Fratto ME, Spoto C, Russo A, Galluzzo S, Zoccoli A, Vincenzi B, Tonini G. Santini D, et al. Among authors: spoto c. Br J Cancer. 2010 Oct 12;103(8):1305; author reply 1306. doi: 10.1038/sj.bjc.6605898. Epub 2010 Sep 14. Br J Cancer. 2010. PMID: 20842127 Free PMC article. No abstract available.
Prognostic Relevance of Objective Response According to EASL Criteria and mRECIST Criteria in Hepatocellular Carcinoma Patients Treated with Loco-Regional Therapies: A Literature-Based Meta-Analysis.
Vincenzi B, Di Maio M, Silletta M, D'Onofrio L, Spoto C, Piccirillo MC, Daniele G, Comito F, Maci E, Bronte G, Russo A, Santini D, Perrone F, Tonini G. Vincenzi B, et al. Among authors: spoto c. PLoS One. 2015 Jul 31;10(7):e0133488. doi: 10.1371/journal.pone.0133488. eCollection 2015. PLoS One. 2015. PMID: 26230853 Free PMC article.
26 results